Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication.

Abstract

OBJECTIVE To analyse through a large multicentre series, morbidity of nephron-sparing surgery (NSS) in relation to tumour size and surgical indication. METHODS The study included patients from eight international academic centres. Age, sex, TNM stage, tumour size, Fuhrman grade, Eastern Cooperative Oncology Group performance status (ECOG-PS), surgical margins, local and distant recurrences, and overall and cancer-specific survival rates were collected and analysed. Indication for elective or mandatory NSS, medical and surgical complication rates, mean blood loss, blood transfusion, and length of hospital stay were specifically recorded for the purpose of this study. Groups were compared for qualitative and quantitative variables by using chi(2) (Fischer exact test) and Student t tests, respectively. RESULTS A total of 1048 NSS procedures were included in this study. Mean tumour size was 3.4+/-2.1cm. In 730 elective procedures mean operative time (p=0.002), mean blood loss (p=0.01), the need for blood transfusion (p=0.001), and urinary fistula rate (p=0.01) were significantly increased for tumours >4 cm. However, these differences did not result in significantly increased medical (p=0.4), surgical complication rates (p=0.6), or length of hospital stay (p=0.9). Finally, in elective procedures for malignant tumours, positive surgical margins, local or distant recurrence rates, and cancer-specific survival were not significantly different in tumours < or =4 cm and >4 cm. CONCLUSION Excellent cancer control and outcomes can be achieved with NSS in carefully selected patients with tumours >4 cm. Expanding the size indication of elective NSS results in an increased but acceptable morbidity.

0500100015002008200920102011201220132014201520162017
Citations per Year

6,605 Citations

Semantic Scholar estimates that this publication has 6,605 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Patard2007MorbidityAC, title={Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication.}, author={Jean-Jacques Patard and Allan J. Pantuck and Maxime Crepel and John S. Lam and Laurent Bellec and Baptiste Albouy and David Lopes and Jean-Christophe Bernhard and François Guill{\'e} and Bertrand Lacroix and Alexandre de la Taille and Laurent Salomon and Christian Pfister and Michel Souli{\'e} and Jacques Tostain and Jean-Marie Ferri{\'e}re and Claude Cl{\'e}ment Abbou and Marc C Colombel and Arie S. Belldegrun}, journal={European urology}, year={2007}, volume={52 1}, pages={148-54} }